Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Sensyne app.... note govt target 100m tests/wk & Excalibur link
“Sensyne Health's app approval 'unequivocally positive', says broker
“We estimate that there will be as many as 100mln per week of these distributed in the UK"
“Sensyne Health PLC’s (LON:SENS) announcement that its MagnifEye app to improve the accuracy of instant Covid-19 tests has received UK regulatory approval is ‘unequivocally positive’, according to broker Liberum.
The MHRA has granted authorisation of special use alongside the Innova lateral flow test.
Innova was the brand originally used to test the MagnifEye technology as part of an NHS Digital pilot study, notes Liberum.
“We believe that all current NHS provided lateral flow tests are the Innova brand,” added the broker.
“We estimate that there will be as many as 100mln per week of these distributed in the UK if the government hits its desired aim of every adult testing themselves twice weekly.”
Sensyne Health receives UK regulatory sign-off for AI technology that automates analysis of COVID lateral flow tests
The broker added there remain many unknowns, such as how or even if MagnifEye will be integrated with these tests, but it opens a route to significant revenues for Sensyne if it can find a way to use today’s approval to strike a commercial agreement with the NHS.
“In terms of the theoretical financial opportunity, even at half the royalty it gets from its current testing partner, Excalibur, the maximum revenue potential would be £4mln per week.
“For context, we forecast total revenues for Sensyne of £27mln for fiscal 2022.”
Shares rose by 2.5% to 167.5p.”
https://www.proactiveinvestors.co.uk/companies/news/948834/sensyne-health-s-app-approval--unequivocally-positive--says-broker-948834.html
Trek
Mr Grant Shapps has suggested to use NHS app to update both vaccinations or covid-19 app or a letter from NHS to prove that they are vaccinated. I wonder if ctea has any part to play in the two apps although I am optimistic. Probably will know on Monday.
Their appears to be some evidence to suggest 1 stock trades means news, but I remain open minded.
Interesting 1 share purchase indeed . Either someone. Is being mischievous or there’s news early next week.
The big buys yesterday suggests something is close .And remember Guy put his shares away just a few weeks ago